Meeting
2021 ASCO Annual Meeting
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.
Authors
Andrea Forschner
Department of Dermatology, University Hospital of Tuebingen, Tuebingen, Germany
Andrea Forschner , Julia Eckardt , Peter Martus , Sorin Armeanu-Ebinger , Stephan Ossowski , Irina Bonzheim , Thomas Eigentler , Teresa Maria Santos Amaral , Lukas Flatz , Claus Garbe , Christopher Schroeder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9524)
DOI
10.1200/JCO.2021.39.15_suppl.9524
Abstract #
9524
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome.
First Author: Jeffrey S. Weber
Poster
2014 ASCO Annual Meeting
Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
First Author: Michael S. Gordon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prevalence and genomic landscape of BRAF alterations across gastrointestinal cancers.
First Author: David Driscoll
Poster
2022 ASCO Annual Meeting
Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.
First Author: Jonathan Daniel Schoenfeld